MetLife Investment Management, LLC - 04 Aug 2020 Form 4 Insider Report for Neuberger Berman High Yield Strategies Fund Inc. (NHS)

Role
10%+ Owner
Signature
/s/ Israel Grafstein, Chief Compliance Officer of MetLife Investment Management, LLC
Issuer symbol
NHS
Transactions as of
04 Aug 2020
Net transactions value
-$1,264,884,481,362,865
Form type
4
Filing time
10 Jun 2022, 16:30:43 UTC
Previous filing
26 May 2022
Next filing
10 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NHS Floating Rate Senior Note, Series A Note, Due Sep. 18, 2023 Other $255,393,458,671,779 -15,969,333 -67% $15992744.26* 7,984,667 04 Aug 2020 See Footnotes F1, F3, F4, F5
transaction NHS Floating Rate Senior Note, Series A Note, Due Sep. 18, 2023 Other $310,966,590,706,838 -17,621,333 -67% $17647166.12* 8,810,667 04 Aug 2020 See Footnotes F1, F3, F4, F5
transaction NHS Floating Rate Senior Note, Series A Note, Due Sep. 18, 2023 Other $698,475,397,982,900 -26,409,334 -67% $26448050.45* 13,204,666 04 Aug 2020 See Footnotes F1, F3, F4, F5
transaction NHS Series B Mandatory Redeemable Preferred Shares Other $49,129,001,348 -1,400 -100% $35092143.82* 0 04 Aug 2020 See Footnotes F2, F3, F4, F5
transaction NHS Series C Mandatory Redeemable Preferred Shares Purchase $62,000,000 +4,960,000 $12.50 4,960,000 04 Aug 2020 See Footnotes F4, F5
transaction NHS Series C Mandatory Redeemable Preferred Shares Purchase $12,000,000 +960,000 $12.50 960,000 04 Aug 2020 See Footnotes F4, F5
transaction NHS Series C Mandatory Redeemable Preferred Shares Purchase $21,000,000 +1,680,000 $12.50 1,680,000 04 Aug 2020 See Footnotes F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These Floating Rate Senior Notes, Series A Notes, due September 18, 2023 ("Notes") were redeemed, in part, by the Issuer pursuant to a partial prepayment of the principal plus accrued and unpaid interest.
F2 These Series B Mandatory Redeemable Preferred Shares ("Series B MRPS") were redeemed, in whole, by the Issuer at a price equal to the liquidation preference of $25,000 per share plus accumulated and unpaid dividends.
F3 This price reflects the aggregate amount received in exchange for the redemption.
F4 These Notes, Series B MRPS and Series C MRPS are held directly by clients for whom the Reporting Person serves as investment manager.
F5 The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Remarks:

The initial Form 3 was filed on October 9, 2013 by Metropolitan Life Insurance Company. Subsequent to that filing, management of positions in the Issuer's securities was transferred to MetLife Investment Management, LLC, who assumed the Section 16 reporting obligations for such positions.